Intrinsic antibody-dependent enhancement of microbial infection in macrophages: Disease regulation by immune complexes

The Lancet Infectious Diseases

Volumn 10, Issue 10, 2010, Pages 712-722

  Halstead, Scott B ^e   Mahalingam, Suresh ^a   Marovich, Mary A ^b   Ubol, Sukathida ^c   Mosser, David M ^d  

^a UNIVERSITY OF CANBERRA   (Australia)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

^d Bldg 142   (United States)

^e International Vaccine Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; ANTIGEN ANTIBODY COMPLEX; IMMUNOGLOBULIN G;

ANTIBODY DEPENDENT ENHANCEMENT; DENGUE; DENGUE VIRUS; DISEASE SEVERITY; HUMAN; IMMUNE COMPLEX DISEASE; INFECTION; LEISHMANIASIS; MACROPHAGE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ROSS RIVER ALPHA VIRUS; ANIMAL; ANTIGEN ANTIBODY COMPLEX; BACTERIA; EUKARYOTE; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; MONOCYTE; PATHOGENICITY; TH1 CELL; TH2 CELL; VIRUS;

ANIMALS; ANTIBODY-DEPENDENT ENHANCEMENT; ANTIGEN-ANTIBODY COMPLEX; BACTERIA; EUKARYOTA; HUMANS; IMMUNOGLOBULIN G; MACROPHAGES; MONOCYTES; RECEPTORS, IGG; TH1 CELLS; TH2 CELLS; VIRUSES;

EID: 77957160633     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70166-3     Document Type: Review

References (124)

1. Hawkes RA Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust J Exp Biol Med Sci 1964, 42:465-482.
2. Hawkes RA, Lafferty KJ The enhancement of virus infectivity by antibody. Virology 1967, 33:250-261.
3. Halstead SB, Nimmannitya S, Yamarat C, Russell PK Hemorrhagic fever in Thailand; recent knowledge regarding etiology. Jpn J Med Sci Biol 1967, 20:96-103.
4. Halstead SB, Chow J, Marchette NJ Immunologic enhancement of dengue virus replication. Nat New Biol 1973, 243:24-26.
5. Halstead SB, O'Rourke EJ Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977, 146:201-217.
6. Kliks S, Halstead SB An explanation for enhanced virus plaque formation in chick embryo cells. Nature 1980, 285:504-505.
7. Kliks S, Halstead SB Role of antibodies and host cells in plaque enhancement of Murray Valley encephalitis virus. J Virol 1983, 46:394-404.
8. Mosser DM, Edwards JP Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
9. Gerber JS, Mosser DM Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors. J Immunol 2001, 166:6861-6868.
10. Factsheet: Leishmania infection Centers for Disease Control and Prevention, Division of Parasitic DiseasesDivision of Parasitic Diseases, (accessed Aug 31, 2010). http://www.cdc.gov/ncidod/dpd/parasites/leishmania/factsht_leishmania.htm.
11. Ghalib HW, Piuvezam MR, Skeiky YA, et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993, 92:324-329.
12. Murray HW, Masur H, Keithly JS Cell-mediated immune response in experimental visceral leishmaniasis. I. Correlation between resistance to Leishmania donovani and lymphokine-generating capacity. J Immunol 1982, 129:344-350.
13. Pearson RD, Romito R, Symes PH, Harcus JL Interaction of Leishmania donovani promastigotes with human monocyte-derived macrophages: parasite entry, intracellular survival, and multiplication. Infect Immun 1981, 32:1249-1253.
14. Fiorentino DF, Bond MW, Mosmann TR Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989, 170:2081-2095.
15. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 1990, 248:1230-1234.
16. Mosser DM, Zhang X Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008, 226:205-218.
17. Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992, 89:1890-1893.
18. O'Garra A, Vieira P T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol 2007, 7:425-428.
19. Heinzel FP, Sadick MD, Mutha SS, Locksley RM Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci USA 1991, 88:7011-7015.
20. Kane MM, Mosser DM The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001, 166:1141-1147.
21. Karp CL, el-Safi SH, Wynn TA, et al. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest 1993, 91:1644-1648.
22. Vieth M, Will A, Schroppel K, Rollinghoff M, Gessner A Interleukin-10 inhibits antimicrobial activity against Leishmania major in murine macrophages. Scand J Immunol 1994, 40:403-409.
23. Miles SA, Conrad SM, Alves RG, Jeronimo SM, Mosser DM A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 2005, 201:747-754.
24. Seder RA, Gazzinelli R, Sher A, Paul WE Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 1993, 90:10188-10192.
25. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993, 177:1505-1509.
26. Carrera L, Gazzinelli RT, Badolato R, et al. Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J Exp Med 1996, 183:515-526.
27. Sutterwala FS, Noel GJ, Clynes R, Mosser DM Selective suppression of interleukin-12 induction after macrophage receptor ligation. J Exp Med 1997, 185:1977-1985.
28. Sutterwala FS, Noel GJ, Salgame P, Mosser DM Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. J Exp Med 1998, 188:217-222.
29. Anderson CF, Lucas M, Gutierrez-Kobeh L, Field AE, Mosser DM T cell biasing by activated dendritic cells. J Immunol 2004, 173:955-961.
30. Gerber JS, Mosser DM Stimulatory and inhibitory signals originating from the macrophage Fcgamma receptors. Microbes Infect 2001, 3:131-139.
31. Murray HW, Moreira AL, Lu CM, et al. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. J Infect Dis 2003, 188:458-464.
32. Buxbaum LU A detrimental role for IgG and FcgammaR in Leishmania mexicana infection. Immunol Res 2008, 42:197-209.
33. Buxbaum LU, Scott P Interleukin 10- and Fcgamma receptor-deficient mice resolve Leishmania mexicana lesions. Infect Immun 2005, 73:2101-2108.
34. Ioan-Facsinay A, de Kimpe SJ, Hellwig SM, et al. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 2002, 16:391-402.
35. Kima PE, Constant SL, Hannum L, et al. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J Exp Med 2000, 191:1063-1068.
36. Padigel UM, Farrell JP Control of infection with Leishmania major in susceptible BALB/c mice lacking the common gamma-chain for FcR is associated with reduced production of IL-10 and TGF-beta by parasitized cells. J Immunol 2005, 174:6340-6345.
37. Mosser DM The many faces of macrophage activation. J Leukoc Biol 2003, 73:209-212.
38. Anderson CF, Gerber JS, Mosser DM Modulating macrophage function with IgG immune complexes. J Endotoxin Res 2002, 8:477-481.
39. Pearson RD, Naidu TG, Young AC, de Alencar JE, Romito R, Davis JS Circulating immune complexes and rheumatoid factors in visceral leishmaniasis. J Infect Dis 1983, 147:1102.
40. Salama MM Rheumatoid factor among several cases of visceral leishmaniasis. J Egypt Soc Parasitol 1990, 20:837-839.
41. Oliveira AV, Rossi MA, Rogue-Barreira MC, et al. The potential role of Leishmania antigens and immunoglobulins in the pathogenesis of glomerular lesions of hamsters infected with Leishmania donovani. Ann Trop Med Parasitol 1985, 79:539-543.
42. Wanasen N, Xin L, Soong L Pathogenic role of B cells and antibodies in murine Leishmania amazonensis infection. Int J Parasitol 2008, 38:417-429.
43. Lucas M, Zhang X, Prasanna V, Mosser DM ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J Immunol 2005, 175:469-477.
44. Yang Z, Mosser DM, Zhang X Activation of the MAPK, ERK, following Leishmania amazonensis infection of macrophages. J Immunol 2007, 178:1077-1085.
45. Flannagan RS, Cosio G, Grinstein S Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. Nat Rev Microbiol 2009, 7:355-366.
46. Maglione PJ, Xu J, Casadevall A, Chan J Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol 2008, 180:3329-3338.
47. Watford WT, Moriguchi M, Morinobu A, O'Shea JJ The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 2003, 14:361-368.
48. Robinson CM, Nau GJ Interleukin-12 and interleukin-27 regulate macrophage control of Mycobacterium tuberculosis. J Infect Dis 2008, 198:359-366.
49. Almeida AS, Lago PM, Boechat N, et al. Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J Immunol 2009, 183:718-731.
50. Schreiber T, Ehlers S, Heitmann L, et al. Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity. J Immunol 2009, 183:1301-1312.
51. Halstead SB Immune enhancement of viral infection. Prog Allergy 1982, 31:301-364.
52. Sauter P, Hober D Mechanisms and results of the antibody dependent enhancement of viral infections and the role in the pathogenesis of coxsackie virus B-induced diseases. Microbes Infect 2009, 11:443-451.
53. Stueckemann JA, Holth M, Swart WJ, et al. Replication of lactate dehydrogenase-elevating virus in macrophages. 2. Mechanism of persistent infection in mice and cell culture. J Gen Virol 1982, 59:263-272.
54. Weiss RC, Scott FW Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immune Microbiol Infect Dis 1981, 4:175-188.
55. Olsen CW A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination. Vet Microbiol 1993, 36:1-37.
56. Yoon KJ, Wu LL, Zimmerman JJ, Hill HT, Platt KB Antibody-dependent enhancement (ADE) of porcine reproductive and respiratory syndrome virus (PRRSV) infection in pigs. Viral Immunol 1996, 9:51-63.
57. Burke DS Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?. Perspect Biol Med 1992, 35:511-530.
58. Mdurvwa EG, Ogunbiyi PO, Gakou HS, Reddy PG Pathogenic mechanisms of caprine arthritis-encephalitis virus. Vet Res Commun 1994, 18:483-490.
59. Mealey RH, Leib SR, Littke MH, Wagner B, Horohov DW, McGuire TC Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen. Vaccine 2009, 27:2453-2468.
60. Porter AD, Larsen AE, Porter HG The pathogenesis of Aleutian disease of mink. II Enhancement of tissue lesions following the administration of a killed virus vaccine or passive antibody. J Immunol 1972, 109:1-7.
61. Kanno H, Wohlinbarger JB, Bloom ME Aleutian mink disease parvovirus infection of mink macrophages and human macrophage cell line *937: demonstration of antibody-dependent enhancement of infection. J Virol 1993, 67:7017-7024.
62. Best SM, Bloom ME Aleutian mink disease parvovirus. The parvoviruses 2006, 457-471. Hodder Arnold, London. J.R. Kerr, S.F. Cotmore, M.E. Bloom, R.M. Linden, C.R. Parrish (Eds.).
63. Gomez-Villamandos JC, Carrasco L, Bautista MJ, et al. African swine fever and classical swine fever: a review of the pathogenesis. Dtsch Tierarztl Wochenschr 2003, 110:165-169.
64. Webster RG, Askonas BA Cross-protection and cross reactive cytotoxic T cells induced by influenza virus vaccines in mice. Eur J Immunol 1980, 10:396-401.
65. Chanock RM, Parrott RH, Kapakian AZ Possible role of immunological factors in pathogenesis of RS virus in lower respiratory tract disease. Perspec Virol 1968, 6:125-135.
66. Fulginiti FA, Eller JJ, Downie AW, Kempe CH Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 1967, 202:1075-1080.
67. King AA, Sands JJ, Porterfield JS Antibody-mediated enhancement of rabies virus infection in a mouse macrophage cell line (P388D1). J Gen Virol 1984, 65:1091-1093.
68. Prabhakar BS, Nathanson N Acute rabies deaths mediated by antibody. Nature 1981, 290:590-5991.
69. Tirado SM, Yoon KJ Antibody-dependent enhancement of virus infection and disease. Viral Immunol 2003, 16:69-86.
70. Burke DS Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?. Perspect Biol Med 1992, 35:511-530.
71. Delgado MF, Coviello S, Monsalvo AC, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009, 15:34-41.
72. Halstead SB, O'Rourke EJ, Allison AC Dengue viruses and mononuclear phagocytes: II. Identity of blood and tissue leukocytes supporting in vitro infection. J Exp Med 1977, 146:218-228.
73. Gollins SW, Porterfield JS Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody on virus fate. J Gen Virol 1984, 65:1261-1272.
74. Gollins SW, Porterfield JS Flavivirus infection enhancement in macrophages: an electron microscopic study of viral cellular entry. J Gen Virol 1985, 66:1969-1982.
75. Olsen C, Scott F Evaluation of antibody-dependent enhancement of feline infectious peritonitis virus infectivity using in situ hybridization. Microb Pathog 1993, 14:275-285.
76. Robinson WE, Montefiori DC, Gillespie DH, Mitchell WM Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J Acquir Immune Defic Syndr 1989, 2:33-42.
77. Linn ML, Aaskov JG, Suhrbier A Antibody-dependent enhancement and persistence in macrophages of an arbovirus associated with arthritis. J Gen Virol 1996, 77:407-411.
78. Suhrbier A, Mahalingam S The immunobiology of viral arthritides. Pharmacol Ther 2009, 124:301-308.
79. Lidbury BA, Mahalingam S Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection. J Virol 2000, 74:8376-8381.
80. Mahalingam S, Lidbury BA Suppression of lipopolysaccharide-induced antiviral transcription factor (STAT-1 and NF-kB) complexes by antibody-dependent enhancement of macrophage infection by Ross River virus. Proc Natl Acad Sci USA 2002, 99:13819-13824.
81. Suhrbier A, La Linn M Suppression of antiviral responses by antibody-dependent enhancement of macrophage infection. Trends Immunol 2003, 24:165-168.
82. Halstead SB, O'Rourke EJ Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977, 265:739-741.
83. Halstead SB Neutralization and antibody dependent enhancement of dengue viruses. Adv Virus Research 2003, 60:421-467.
84. Halstead SB, Venkateshan CN, Gentry MK, Larsen LK Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies. J Immunol 1984, 132:1529-1532.
85. Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328:745-748.
86. Kliks SC, Nimmannitya S, Nisalak A, Burke DS Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988, 38:411-419.
87. Jessie K, Fong MY, Devi S, Lam SK, Wong KT Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in site hybridization. J Infect Dis 2004, 189:1411-1418.
88. Balsitis SJ, Coloma J, Castro G, et al. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Am J Trop Med Hyg 2009, 80:416-424.
89. Cohen SN, Halstead SB Shock associated with dengue infection. I. Clinical and physiologic manifestations of dengue hemorrhagic fever in Thailand, 1964. J Pediatrics 1966, 68:448-456.
90. Bethell DB, Flobbe K, Cao XT, et al. Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J Infect Dis 1998, 177:778-782.
91. Green S, Vaughn DW, Kalayanarooj S, et al. Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. J Med Virol 1999, 59:329-334.
92. Chareonsirisuthigul T, Kalayanarooj S, Ubol S Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol 2007, 88:365-375.
93. Ubol S, Phuklia W, Kalayanarooj S, Modhiran N Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis 2010, 201:923-935.
94. Chen LC, Lei HY, Liu CC, et al. Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am J Trop Med Hyg 2006, 74:142-147.
95. Simmons CP, Popper S, Dolocek C, et al. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J Infect Dis 2007, 195:1097-1107.
96. Nguyen TH, Lei HY, Nguyen TL, et al. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis 2004, 189:221-232.
97. Ubol S, Masrinoul P, Chaijaruwanich J, Kalayanarooj S, Charoensirisuthikul T, Kasisith J Differences in global gene expression in peripheral blood mononuclear cells indicate a significant role of the innate responses in progression of dengue fever but not dengue hemorrhagic fever. J Infect Dis 2008, 197:1459-1467.
98. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, Harris E Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 2004, 78:2701-2710.
99. Shresta S, Sharar KL, Prigozhin DM, Snider HM, Beatty PR, Harris E Critical roles for both STAT1-dependent and STAT1-independent pathways in the control of primary dengue virus infection in mice. J Immunol 2005, 175:3946-3954.
100. Navarro-Sanchez E, Despres P, Cedillo-Barron L Innate immune responses to dengue virus. Arch Med Res 2005, 36:425-435.
101. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000, 181:2-9.
102. Libraty DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002, 185:1213-1221.
103. Hsieh MF, Lai SL, Chen JP, et al. Both CXCR3 and CXCL10/IFN-inducible protein 10 are required for resistance to primary infection by dengue virus. J Immunol 2006, 177:1855-1863.
104. Chen JP, Lu HL, Lai SL, et al. Dengue virus induces expression of CXC chemokine ligand 10/IFN-gamma-inducible protein 10, which competitively inhibits viral binding to cell surface heparan sulfate. J Immunol 2006, 177:3185-3192.
105. Miller JL, deWet BJ, Martinez-Pomares L, et al. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog 2008, 4:e17.
106. Boonnak K, Slike BM, Burgess TH, et al. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol 2008, 82:3939-3951.
107. Chaturvedi UC, Raghupathy R, Pasca AS, et al. Shift from a Th1-type response to Th1-type in dengue haemorrhagic fever. Curr Sci 1999, 76:63-69.
108. Zellweger RM, Prestwood TR, Shresta S Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 2010, 7:128-139.
109. Balsitis SJ, Williams KL, Lachica R, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 2010, 6:e1000790.
110. Halstead SB, Porterfield JS, O'Rourke EJ Enhancement of dengue virus infection in monocytes by flavivirus antisera. Am J Trop Med Hyg 1980, 29:638-642.
111. Putvatana R, Yoksan S, Chayayodhin T, Bhamarapravati N, Halstead SB Absence of dengue 2 infection enhancement in human sera containing Japanese encephalitis antibodies. Am J Trop Med Hyg 1984, 33:288-294.
112. Petersen NC, Boyle JF Immunologic phenomena in the effusive form of feline infectious peritonitis. Am J Vet Res 1980, 41:868-876.
113. Vennema H, DeGroot RJ, Harbour DA, et al. Early death after feline infectious peritonitis challenge due to recombinant vaccinia virus immunization. J Virol 1990, 64:1407-1409.
114. Vennema H, Poland A, Foley J, Pedersen NC Feline infectious peritonitis viruses arise by mutation from endemic feline enteric coronaviruses. Virology 1998, 243:150-157.
115. Porter DDL, Larsen AE, Porter HG Aleutian disease of mink. Adv Immunol 1980, 29:261-286.
116. Porter DD, Larsen AE, Porter HG The pathogenesis of Aleutian disease of mink. I. In vivo viral replication and the host antibody response to viral antigen. J Exp Med 1969, 130:575-593.
117. Cancel-Tirado SM, Evans RB, Yoon KJ Monoclonal antibody analysis of porcine reproductive and respiratory syndrome virus epitopes associated with antibody-dependent enhancement and neutralization of virus infection. Vet Immunol Immunopathol 2004, 102:249-262.
118. Vanhee M, Costers S, Van Breedam W, Geldhof MF, Van Doorsselaere J, Nauwynck HJ A variable region in GP4 of European-type porcine reproductive and respiratory syndrome virus induces neutralizing antibodies against homologous but not heterologous virus strains. Viral Immunol 2010, 23:403-413.
119. Kimman TG, Cornelissen LA, Moormann RJ, Rebel JM, Stockhofe-Zurwieden N Challenges for porcine reproductive and respiratory syndrome virus (PRRSV) vaccinology. Vaccine 2009, 27:3704-3718.
120. Van Breedam W, Van Gorp H, Zhang JQ, Crocker PR, Delputte PL, Nauwynck HJ The M/GP(5) glycoprotein complex of porcine reproductive and respiratory syndrome virus binds the sialoadhesin receptor in a sialic acid-dependent manner. PLoS Pathog 2010, 6:e1000730.
121. Jung K, Renukaradhya GJ, Alekseev KP, Fang Y, Tang Y, Saif LJ Porcine reproductive and respiratory syndrome virus modifies innate immunity and alters disease outcome in pigs subsequently infected with porcine respiratory coronavirus: implications for respiratory viral co-infections. J Gen Virol 2009, 90:2713-2723.
122. Nimmerjahn F, Ravetch JV Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008, 8:34-47.
123. Moi ML, Lim CK, Takasaki T, Kurane I Involvement of the Fc{gamma} receptor IIA cytoplasmic domain in antibody-dependent enhancement of dengue virus infection. J Gen Virol 2010, 91:103-111.
124. Fink J, Gu F, Vasudevan SG Role of T cells, cytokines and antibody in dengue fever and dengue haemorrhagic fever. Rev Med Virol 2006, 16:263-275.